

IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Allerson, et al. Confirmation No.: 5641

Application No.: 10/701,007 Group Art Unit: 1645

Filing Date: November 4, 2003 Examiner: Not Yet Assigned

For: COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED

NUCLEOSIDES FOR USE IN GENE MODULATIONS

EXPRESS MAIL LABEL NO: EV325730128US DATE OF DEPOSIT: March 18, 2005

EV325730128US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Ş

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).
	Copies of reference numbers listed on the attached Form PTO-1449 are
	enclosed herewith.
\boxtimes	A copy of reference number 135 on the attached Form PTO 1449 is not
	required to be submitted pursuant to waiver of 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.
The refollow	elevance of those listed references which are not in the English language is as

DOCKET NO.: ISIS-5325

- 3 -

PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: March 17, 2005

John A. Harrelson, Jr. Registration No. 42,637

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW



Docket No. Application No. Form PTO-1449 Modified 10/701,007 ISIS-5325 List of Patent and Publications **Applicant** Cited by Applicant Charles Allerson, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office November 4, 2003 1645 Confirmation No. 5641 **U. S. PATENT DOCUMENTS** Examiner **Document Initial** No. Date Name Class Subclass * 135 2002/0081736 A1 06/27/02 Conroy, et al. 435 455 FOREIGN PATENT DOCUMENTS Examiner Translation Initial Document No. Date Country YES NO

DATE CONSIDERED

EXAMINER

^{*} Cited on the PCT Written Opinion dated March 7, 2005 (PCT/US03/35146).